Anthony Doolittle

Anthony Doolittle


Email [email protected]​

Phone +44 20 7296 7226

Fax +44 20 7296 2001

Practice groupCorporate & Finance

Anthony Doolittle is a partner in the firm's corporate practice in London. His practice covers a wide range of transactions, including public and private M&A, joint ventures, and equity capital markets work.  

Anthony has developed in-depth knowledge in the financial services, insurance, life sciences, and energy sectors. Before joining Hogan Lovells, Anthony was a senior associate in the corporate department of a Magic Circle law firm.

Awards and recognitions


"Key lawyer" in Tier 1 Fintech team
Legal 500

Education and admissions


B.A. Modern History, University of Oxford, 2007

Bar admissions and qualifications

Solicitor, England and Wales

Representative experience

AmerisourceBergen on its US$6.47 billion acquisition of Alliance Healthcare from Walgreens Boots Alliance.

Norwegian Air Shuttle on its joint venture with CCB Leasing Corporation, a subsidiary of China Construction Bank Corporation, to finance, own and lease 27 aircraft.

Qatar Insurance Company on its participation in a £200m investment by Pollen Street Capital in the insurance broker, Markerstudy, and QIC’s ongoing partnership with Markerstudy.

Goldman Sachs in connection with its investments in Nutmeg, Starling Bank, Trussle and other fintechs.

ISTARI on its cornerstone investment in Sonrai Security as part of its $50m series C fundraising.

Innogy SE on the combination of its subsidiary, Npower, with the domestic retail business of SSE to form a new listed energy retail company.


Vodafone on the combination of Vodafone Netherlands with the Netherlands business of Liberty Global.


Standard Life plc on the recommended offer and scheme of arrangement to acquire Aberdeen Asset Management plc for share-for-share consideration.


The Innovation Group plc on the recommended offer by the Carlyle Group and scheme of arrangement to acquire the company for £499 million.


Actelion on the future collaboration aspects of the acquisition by Johnson & Johnson of Actelion for $30 billion and spin-out of a new research company, Idorsia.


Loading data